×
VRAIn Medical

VRAIn Medical

Software for the automated visualization and analysis of biomedical images

ESADE BAN
Inversor de referencia ESADE BAN
Ticket IR: €65,000
€751,443
68,3%
€645,000 + €106,443
59
Interesados
59
Inversores
35
días restantes
Invierte en menos de 5 min.

Understanding the investment opportunity

VRAIn is a Digital Health startup founded in 2020 and based in Barcelona. The company develops cutting-edge software solutions for the medical sector.

Its technology is a cloud platform for the visualization and automated analysis of biomedical images (DICOMs). This technology combines Virtual Reality (VR), Artificial Intelligence (AI) and Cloud processing to create an immersive and multidimensional spatial computing environment.

VRAIn's first product on the market is AthleteVR, a Software as a Service (SaaS) tool for medical diagnosis support, focused on Traumatology and Sports Medicine and aimed at private clinics in the sector and professional sports clubs.

AthleteVR highlights subtle details of the musculoskeletal system and its soft tissues that are ambiguous with conventional techniques.

AthleteVR transforms any complex musculoskeletal Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) scan into an Immersive Digital Twin (IDT), a supremely intuitive and accurate visualization of the anatomical condition in question.

It aims and succeeds at avoiding many unnecessary surgeries, prioritizing non-surgical and less invasive treatments.





For the doctor, it represents a paradigm shift: moving from "just looking at" scans to capturing their entire true meaning.

For the patient, it means avoiding unnecessary surgeries and moving from being a passive spectator of their pathology to following medical explanations and actively participating in their own recovery.







Musculoskeletal (MSK) conditions are a massive health problem, affecting 50% of the adult population, accounting for 40% of primary care visits, and are increasing due to population aging. (Sources: National Library of Medicine, Evernorth Health Services, Frontiers, Family Medicine).

Currently, ambiguity in conventional medical imaging and 3D models causes clinical uncertainty. This lack of clarity, especially in the diagnosis of soft tissues (muscles, tendons, ligaments, and menisci), can lead to unnecessary surgeries or surgeries with incomplete information, which entails health risks and associated costs that are unmanageable for most healthcare systems.

In professional sports, this ambiguity translates directly into lost competitions for clubs, compromised sports careers for players, and the devaluation of their transfer value.

The company aspires to turn its product into the new gold standard of healthcare in musculoskeletal medical care. AthleteVR seeks to be the essential prerequisite step before any trauma surgery, ensuring that preventive or less invasive treatments are alternatively considered, thus avoiding unnecessary interventions.

Currently, VRAIn already has recurring revenue from two private sports medicine clinics, with a third in the contracting process.

Furthermore, the startup has a paid pilot agreement with a leading pharmaceutical company, as well as ongoing discussions with top-tier sports clubs and competitions, including MotoGP, the Toronto Raptors (NBA), one of the most prominent First Division football clubs, and Hiopos Bàsquet Club (ACB).



IMPORTANT NOTICE

Investors who complete their investment by signing the subscription agreement by 25 January 2026 (inclusive) will receive a 10% bonus on equity. Once the funding round closes, the equity allocation corresponding to the invested amount will be calculated, and the company will top up an additional 10% of shares at no extra cost.

Investors completing their investment by signing the subscription agreement between 26 January 2026 and 8 February 2026 (inclusive) will receive a 6% equity bonus, applied once the round closes, under the same terms outlined above.

Furthermore, exclusively during these two phases, confirmed investors will have access to their own Digital Immersive Twin (DIT), allowing them to experience the company’s technology firsthand. VRAIn Medical will deliver an immersive video generated from the investor’s medical imaging, following this process:

  • Processing the images with our proprietary technology to create a multidimensional, highly accurate, and data-rich replica of the anatomy (DIT).
  • Exploring the model from multiple perspectives, both internal and external, within an immersive Virtual Reality (VR) environment.
  • Capturing the experience in an MP4 video, narrated by the company’s medical team.

INVESTMENT STAGE

SCALEUP

MARKET

  • virtual-reality
  • biotech
  • artificial-intelligence
  • (+2)

OFFICIAL WEBPAGE

Fiscal benefits

Investing in VRAIn Medical offers you fiscal benefits
VIDEOS

VRAIn Medical Team

Daniel Esteban-Ferrer CEO
Daniel Esteban-Ferrer
CEO

Jordi Carbó CIO
Jordi Carbó
CIO

Azucena Rodríguez COO
Azucena Rodríguez
COO

Pau Serra

Pau Serra

Medical Lead

Inversores actuales
ESADE BAN

ESADE BAN

BUSINESSANGEL

Economistes BAN

Economistes BAN

INVESTOR

Felix González

Felix González

BUSINESSANGEL

Accelerators
Barcelona Activa

Barcelona Activa

INCUBATOR

Lanzadera

Lanzadera

ACCELERATOR

Wayra

Wayra

ACCELERATOR

Motivos para invertir Ver más datos


Market Opportunity

  • The Musculoskeletal (MSK) health problem is massive and growing, impacting global health systems and elite sports. VRAIn operates in a large and high-growth niche with direct competition still incipient. This is a blue ocean where the company can navigate thanks to its technological innovation, something its competitors are not yet doing.

Product and Traction

  • AthleteVR is the solution. The MVP is already on the market generating revenue and is currently being used as a patient engagement tool (by one of the leading pharmaceutical companies at a national level). It has attracted the interest of top-tier teams, including MotoGP and one of the main First Division football clubs. With medical regulatory approval expected by the end of 2026, it will become a diagnostic support tool.

Technology and Competitive Advantage

  • The underlying technology is the result of five years of in-house development with a common, robust, and versatile software architecture. Its modular design allows for agile and flexible adaptation to specific market needs (go-to-market), ensuring a sustainable advantage that the company will patent with the financing from this investment round.

Intellectual Property

  • VRAIn has a clear roadmap to protect its innovation. The international patent registration for the next version of AthleteVR is planned for January 2026 and will cover the European and US markets.

Human Capital

  • The main competitive advantage is the team, which combines deep knowledge in disruptive technologies (VR, AI, The Cloud) with expertise in the Health and Sports sectors, combining IT and business profiles. The team has been recognized by national and European institutions, and has invested their personal capital in VRAIn, which demonstrates their total commitment.

Business Model and Scalability

  • AthleteVR's SaaS model is highly scalable by definition. The go-to-market strategy is already proven, with recurring revenue from two private clinics (Elit Medicine and Kroton). The agreement with a major pharmaceutical company provides access to more than 500 musculoskeletal clinics only in Spain, and direct discussions with Key Opinion Leaders (KOLs) in organizations such as the Toronto Raptors and MotoGP open direct channels for business and validation

Objectives

  • Objectives for the coming years are directed towards international expansion, obtaining intellectual property, and regulatory certification. VRAIn only needs the strategic investment to unlock its potential and execute the defined roadmap.

Proven, Reliable, and Scalable Marketing Strategy

  • Growth Marketing Strategy and free trial of the AthleteVR platform: The combination of both attracts a large user base and generates a powerful funnel for capturing users interested in the Basic, Advanced, or Elite paid subscription services.
  • KOL Strategy in Health and Sports: The pilot study with a major pharmaceutical company and, likely, the future agreement with one of the world’s top football clubs provides AtheleVR with credible and immediate access to hundreds of client clinics and clubs, drastically reducing its Customer Acquisition Cost (CAC) and shortening its sales cycle.

¿Quién es el inversor de referencia?

ESADE BAN

ESADE BAN

STARTUP

Ticket IR: €65,000
WEB OFICIAL www.esadeban.com/
Sobre ESADE BAN
ESADE BAN es una red de inversores privados promovida por el Club Emprendedores e Inversores ESADE Alumni y tiene por objetivo dinamizar la actividad emprendedora e inversora en España. Para ello, se propone hacer crecer el tejido financiero de nuestro país reclutando, educando y coordinando la que queremos que sea la mayor red de inversores privados (business angels) del país por número de operaciones. ESADE BAN está focalizada sobre todo en el impulso de empresas de nueva creación o en las primeras fases de crecimiento. El modelo preferido de inversión de los asociados de nuestra red es la co-inversión con otros miembros de la red o con empresas de capital riesgo.
  • Investing in startups: Since 2008
  • Euros invested: €48M
  • Investments:317
  • EXITS:20%
¿Por qué invierto en VRAIn Medical?

Fernando Zallo (Director of ESADE BAN):

"We saw a very remarkable technology and team in VRAIn from the beginning, which is why we invited them to the Barcelona forums, the Madrid forums, and the DeepTech forum we organized with the best universities. At ESADE BAN, we are very selective, and the fact that VRAIn has managed to raise €65k is a very important milestone and gives recognition to their great work. We believe the EXIT will be very profitable."


Dr. Ramon Ciurana (Lead Investor of ESADE BAN):

"As a medical professional, I was already decided to invest in VRAIn since their initial presentation. However, any residual doubts were immediately dispelled upon observing their functionalities and extraordinary potential firsthand.

While three-dimensional reconstruction from CT or MRI images is not an innovation in itself, the ability to interact with these images using virtual reality allows one to surf through anatomical structures, permitting travel inside a bone, a blood vessel, or a lung. This level of exploration is not only an unprecedented experience for the healthcare professional but also for the patient.

Medical practice fundamentally rests on trust between doctor and patient. In this sense, when the patient can visualize their own pathology—be it a fracture, an injury, or an atheroma plaque in an artery—and understand it directly and see the evolution of their process, trust and security are exponentially enhanced. This strengthens the therapeutic relationship and encourages more informed decision-making."

También ha invertido en...
Directo
Chat

Necesitas estar registrado para ver el contenido

Este contenido es confidencial y es necesario que estés registrado en Startupxplore para poder acceder.

Registrarme

Análisis oportunidad Última actualización 12-ene-2026 12:05:01

Necesitas estar registrado para ver el contenido

Este contenido es confidencial y es necesario que estés registrado en Startupxplore para poder acceder.

Registrarme

Preguntas del inversor

La normativa que regula la actividad de Startupxplore requiere que ningún inversor esté en posesión de más información que el resto. Por ello, en esta sección aparecerán las respuestas a cualquier pregunta formulada por un inversor sobre la oportunidad.

Si tienes cualquier duda o cuestión sobre la startup, el proceso o cualquier otro aspecto por favor escríbenos a coinversion@startupxplore.com

Necesitas estar registrado para ver el contenido

Este contenido es confidencial y es necesario que estés registrado en Startupxplore para poder acceder.

Registrarme

Documentación

Necesitas estar registrado para ver el contenido

Este contenido es confidencial y es necesario que estés registrado en Startupxplore para poder acceder.

Registrarme
Importante

La inversión en startups y empresas de reciente creación tiene riesgos asociados, entre los que se incluyen: riesgo de iliquidez, riesgo de información, riesgo de pérdida de parte o el total del capital invertido, entorno operativa rápidamente cambiante, riesgos regulatorios y legales, riesgo por inversión minoritaria, sin capacidad de influir sobre la gestión de la compañía. Por la elevada incertidumbre que tiene este tipo de inversión, únicamente se debería contemplar invertir si se entienden estos riesgos y siempre como parte de una cartera lo suficientemente diversificada.

Pulsa aquí para leer la "información básica para el cliente" antes de invertir en las operaciones de co-inversión sindicada.

Startupxplore trabaja con inversores de reconocido prestigio y aplica una política estricta para la gestión de los conflictos de intereses, de esa forma tratamos de asegurar que los proyectos publicados tienen una base sólida pero, de ningún modo, Startupxplore podrá ser responsable por las decisiones de inversión que los miembros de su plataforma tomen, así como por las opiniones y comentarios que las empresas publiquen en la misma.

Startupxplore trabaja con inversores de reconocido prestigio y aplica una política estricta para la gestión de los conflictos de intereses, de esa forma tratamos de asegurar que los proyectos publicados tienen una base sólida pero, de ningún modo, Startupxplore podrá ser responsable por las decisiones de inversión que los miembros de su plataforma tomen, así como por las opiniones y comentarios que las empresas publiquen en la misma.

De conformidad con el REGLAMENTO (UE) 2020/1503 DEL PARLAMENTO EUROPEO Y DEL CONSEJO, te informamos de que, al igual que todas las plataformas de servicios de financiación participativa, Startupxplore cumple con la normativa vigente y, en especial, con:

PERIODO DE REFLEXIÓN PRECONTRACTUAL

Existe un período de reflexión precontractual para los inversores no experimentados durante el cual podrán revocar su expresión de interés en la oferta de financiación participativa sin necesidad de justificar su decisión y sin incurrir en una sanción. Dicho período de reflexión comenzará en el momento de la expresión de interés por parte del inversor no experimentado y expirará al término de cuatro días naturales. La forma de revocar una expresión de interés será por medio de correo electrónico a ops@startupxplore.com desde la misma dirección de correo desde la que el inversor no experimentado manifestó su interés en la oferta de financiación participativa. Inmediatamente después de la recepción de la oferta de inversión o de la manifestación de interés, Startupxplore informará al inversor no experimentado potencial, a través de su plataforma de financiación participativa, de que ha comenzado el período de reflexión.

FALTA DE COBERTURA POR EL FONDO DE GARANTÍA DE DEPÓSITOS

Los servicios de financiación participativa no están cubiertos por el sistema de garantía de depósitos establecido de conformidad con la Directiva 2014/49/UE. Los valores negociables o los instrumentos admitidos para la financiación participativa adquiridos a través de esta plataforma de financiación participativa no están cubiertos por el sistema de indemnización de los inversores establecido de conformidad con la Directiva 97/9/CE.

Haz scroll para continuar...